Integra Lifesciences Holdings Corp (IART) FinancialsIARTFinancialIntegra Lifesciences Holdings Corp

Integra LifeSciences Holdings Corporation (IART) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Neurosurgery, accounting for 50.9% of total sales, equivalent to $213.26M. Other significant revenue streams include Wound Reconstruction and Care and Instruments. Understanding this composition is critical for investors evaluating how IART navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Integra LifeSciences Holdings Corporation maintains a gross margin of 54.90%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.86%, while the net margin is 1.07%. These profitability ratios, combined with a Return on Equity (ROE) of -0.70%, provide a clear picture of how effectively IART converts its operational activities into shareholder value.

In the context of the broader market, IART competes directly with industry leaders such as AORT and DRTS. With a market capitalization of $1.43B, it holds a leading position in the sector. When comparing efficiency, IART's gross margin of 54.90% stands against AORT's 64.03% and DRTS's N/A. Such benchmarking helps identify whether Integra LifeSciences Holdings Corporation is trading at a premium or discount relative to its financial performance.

Integra Lifesciences reported Q2 2026 revenue of $418.8 million, slightly flat year-over-year, but with an adjusted EPS of $0.56, exceeding analyst expectations. The gross margin is relatively stable at 54.90% for Q2 2026, indicating operational efficiency despite cost pressures.